The goal of developing a 5 billion single-cell atlas within the next three years took a big step forward with the recent announcement of a new effort between longstanding partners Illumina and Broad Clinical Labs to rapidly streamline and scale single-cell workflows. Broad Clinical Labs will utilize Illumina’s Single Cell Prep, NovaSeq™ X Plus platform, 25B flow cell, and DRAGEN™ analysis software workflow, along with our cutting-edge Perturb-seq, CRISPR screens, and other platforms, to help researchers rapidly process and analyze single-cell samples at unprecedented volumes. This collaboration promises to unlock large-scale functional genomics studies that will accelerate the understanding of disease and propel drug development.
Read more about the collaboration here.